Oncomine analysis results showed that in several solid tumors, the expression of SLC2A5 was more significant in lung cancer, lymphatic cancer, brain and CNS cancer, and breast cancer, while the expression rate of SLC2A5 in other cancers such as gastric cancer, ovarian cancer, and other cancers was lower (Figure 1(a)). This evidence concerns the gene SLC2A5 and central nervous system cancer.